COVID-19 and cancer treatment

Launched: June 1, 2020
Length: 45 minutes
Dr Rebecca Ann C. Auer, MD, MSc, FRCSC
Dr Christopher Bredeson, MD MSc FRCPC
Dr Paul Wheatly-Price, BSc, MBChB, FRCP (UK), MD
Dr Jean-Marc Bourque, MD, MScPH, FRCPC

Webinar overview: In this webinar, a panel of expert doctors answer common questions about the impact of COVID-19 on cancer treatment across Canada. For example, what is the status of clinical trials? When can loved ones accompany someone receiving treatment? And how will the healthcare system help if someone receiving treatment contracts COVID- 19?


Dr Rebecca Ann C. Auer
Scientific Director, Cancer Therapeutics Program, Ottawa Hospital Research Institute
Surgical Oncologist, Ottawa Hospital
Associate Professor, Department of Surgery and the Department of Biochemistry, Microbiology and Immunology, University of Ottawa

Dr Christopher Bredeson
Head, Malignant Hematology and SCT, Ottawa Hospital
Professor of Medicine, University of Ottawa

Dr Paul Wheatly-Price
Medical Oncologist, Ottawa Hospital Cancer Centre
President of Lung Cancer Canada
Associate Professor, Department of Medicine, University of Ottawa

Dr Jean-Marc Bourque
Radiation Oncologist and Assistant Professor, University of Ottawa
Adjunct professor, McGill University

Picture of Rebecca Ann C. Auer, Christopher Bredeson, Paul Wheatley-Price, Jean-Marc Bourque